Bispecific Antibody Therapies in Multiple Myeloma: Revolutionizing Treatment
Panelists discuss how bispecific antibody therapies are revolutionizing multiple myeloma treatment by providing highly effective, accessible options for heavily pretreated patients while addressing key implementation challenges including patient selection, sequencing strategies, safety management protocols, and the transition from academic centers to community-based care delivery.
EP. 1: Treatment Decision-Making in Multiple Myeloma at First and Subsequent Relapses
September 30th 2025Panelists discuss how patient preferences for treatment-free intervals are increasingly important in therapy selection, with bispecifics offering potential for response-adapted dosing and early discontinuation while maintaining remissions.
EP. 2: Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM
September 30th 2025Panelists discuss how bispecifics are reversing the historical paradigm of diminishing returns in relapsed/refractory multiple myeloma, achieving 60% to 70% response rates lasting over a year in heavily pretreated patients.
